Synthetic Biology
-
eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout NCTx on Grow Everything Podcast
eXoZymes (NASDAQ:EXOZ) unveils AI-programmed exozymes, cell-free enzyme systems enabling scalable, sustainable chemical synthesis beyond cellular constraints. First commercial entity NCTx targets NAFLD—affecting 25% globally—via streamlined production eliminating downstream metabolomics. Backed by DoD/DOE grants, the platform advances biofuels and therapeutics with modular integration, avoiding fermentation inefficiencies. Framed as a SaaS model for enzyme licensing, it challenges legacy competitors while investors monitor NAFLD proof-of-concept data and partner deal terms.
